Information  X 
Enter a valid email address

Oxf Biomedica Ord 1P (OXB)

Date Time Source Announcement
03 May 2022 5:18 pm
RNS
Grant of options
  4:46 pm
RNS
Director/PDMR Shareholding
  10:35 am
RNS
Total Voting Rights
29 Apr 2022 5:42 pm
RNS
Directors Dealings / Market Share Purchases
28 Apr 2022 2:24 pm
RNS
Director/PDMR Shareholding
27 Apr 2022 2:58 pm
RNS
2021 Annual report and accounts & AGM notification
  12:10 pm
RNS
PDMR Dealings / Market Share Purchase
21 Apr 2022 4:41 pm
RNS
Director Share Purchase
  1:24 pm
RNS
Directors Dealings / Market Share Purchase
  10:16 am
RNS
Director/PDMR Shareholding
20 Apr 2022 3:45 pm
RNS
Director/PDMR Shareholding
  7:00 am
RNS
Preliminary Results
13 Apr 2022 7:00 am
RNS
Board Appointment
04 Apr 2022 11:34 am
RNS
Notice of Preliminary Results
01 Apr 2022 6:30 pm
RNS
Holding(s) in Company
  10:33 am
RNS
Block listing Application
  9:34 am
RNS
Total Voting Rights
31 Mar 2022 6:07 pm
RNS
Holding(s) in Company
30 Mar 2022 1:00 pm
RNS
Holding(s) in Company
25 Mar 2022 5:15 pm
RNS
Holding(s) in Company
21 Mar 2022 10:44 am
RNS
Long Term Incentive Plan Option Grant
15 Mar 2022 11:25 am
RNS
Holding(s) in Company
  9:39 am
RNS
Holding(s) in Company
11 Mar 2022 4:51 pm
RNS
Holding(s) in Company
  12:00 pm
GNW
Oxford Biomedica broadens its viral vector capabilities with the launch of Oxford Biomedica Solutions, a full scope AAV business in Boston, following closing of its deal with Homology
  9:01 am
RNS
Admission of Conditional Placing Shares
10 Mar 2022 5:32 pm
RNS
Completion of Transaction
09 Mar 2022 11:42 am
RNS
Director Declaration
08 Mar 2022 3:54 pm
RNS
Result of General Meeting
01 Mar 2022 9:52 am
RNS
Total Voting Rights
16 Feb 2022 11:41 am
RNS
Publication of Circular & Notice of GM
04 Feb 2022 8:22 am
RNS
Admission of Firm Placing Shares
01 Feb 2022 9:06 am
RNS
Total Voting Rights
  7:00 am
RNS
Update to agreement with Sio Gene Therapies
31 Jan 2022 9:13 pm
GNW
Oxford Biomedica announces update to agreement with Sio Gene Therapies
  11:21 am
RNS
Market Share Purchase
28 Jan 2022 5:59 pm
RNS
Result of Placing and PrimaryBid offer
  2:04 pm
RNS
Holdings in Company
  7:39 am
GNW
Oxford Biomedica broadens leading viral vector offerings by incorporating Homology Medicines’ established AAV capabilities into a newly formed AAV Manufacturing and Innovation Business in the US with Homology Medicines as 20% owner
  7:38 am
RNS
Retail offer by PrimaryBid
  7:24 am
RNS
US Agreement and Proposed Placing of Shares
17 Jan 2022 7:00 am
RNS
John Dawson to retire from Oxford Biomedica
05 Jan 2022 7:00 am
RNS
Oxford Biomedica Agreement with Cabaletta Bio
04 Jan 2022 11:07 am
RNS
Block listing Return
  10:32 am
RNS
Total Voting Rights
  7:00 am
RNS
John Dawson awarded CBE in New Year Honours List
14 Dec 2021 7:00 am
RNS
Board Appointment
13 Dec 2021 7:00 am
RNS
Oxford Biomedica Updates Lentiviral Agreement
  7:00 am
RNS
Oxford Biomedica Signs Agreement with Arcellx
01 Dec 2021 9:49 am
RNS
Total Voting Rights
01 Nov 2021 10:08 am
RNS
Long Term Incentive Plan Option Grant
  10:02 am
RNS
Total Voting Rights
19 Oct 2021 7:00 am
RNS
Boehringer Ingelheim Exercises Option
01 Oct 2021 9:51 am
RNS
Total Voting Rights
29 Sep 2021 5:54 pm
RNS
Holding(s) in Company
  5:36 pm
RNS
Directors Dealings / Market Share Purchases

a d v e r t i s e m e n t